Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2012

View Archived Issues

Plant-based platform developed for production of antimalarial drug

Takeda identifies benzazepine derivatives for treatment of obesity

Selective GlyT2 inhibitor shows promising analgesic effects in vivo

Mochida reports potent in vivo analgesic activity for proprietary drug

European team generates water-stable, helicate-like products as potential antimicrobials

Oleanolic acid derivative shows promise in model of MS

New panthetheinase inhibitors presented to treat malaria

Exonhit discloses novel tubulin polymerization inhibitors

Boehringer Ingelheim synthesizes novel chemokine CCR2 receptor antagonists

GlaxoSmithKline enrolling toddlers in phase I pneumococcal vaccine trial

Recruitment begins in phase III BEACON study

New phosphodiesterase inhibitors prepared at IntraCellular Therapies

Cardiolynx patents new pioglitazone derivatives

Novel peptide conjugates for bacterial infections designed in Canada

Lundbeck launches antiepileptic tablet in U.S.

Resubmitted pixantrone NDA to be reviewed by FDA's ODAC

New alpha-glucosidase inhibitors developed in Spain

Phase IIb trial of photodynamic therapy for cervical intraepithelial neoplasia advances

Phylogica enters new collaboration involving Phylomer peptide platform

Enrollment in phase II KRN-321 study begins in Japan

Agile Therapeutics completes phase III program for contraceptive patch

Advaxis to raise additional funding with sale of convertible promissory notes

Tivozanib superior to sorafenib in phase III study

Alnylam reports encouraging preclinical data on RNAi therapeutic for Huntington's disease

Glenmark begins pivotal study of antidiarrheal drug in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...